CINPHA logo

Cinclus Pharma Holding AB (publ) Stock Price

OM:CINPHA Community·SEK 878.6m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 4 Fair Values set on narratives written by author

CINPHA Share Price Performance

SEK 0
-21.16 (-100.00%)
SEK 55.00
Fair Value
SEK 0
-21.16 (-100.00%)
Price SEK 0

CINPHA Community Narratives

AnalystConsensusTarget·
Fair Value SEK 55 65.7% undervalued intrinsic discount

Advancing Late-Stage GERD Studies Will Drive Substantial Long-Term Upside

0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AnalystLowTarget·
Fair Value SEK 50 62.2% undervalued intrinsic discount

Clinical And Regulatory Obstacles Will Challenge Gastroenterology Prospects Despite Optimism

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystHighTarget·
Fair Value SEK 75 74.8% undervalued intrinsic discount

Linaprazan Glurate Will Revolutionize Global Gastrointestinal Care

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Trending Discussion

Updated Narratives

CINPHA logo

CINPHA: FDA Guidance Will Support Pivotal Phase III Trial Momentum

Fair Value: SEK 55 65.7% undervalued intrinsic discount
4 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
CINPHA logo

Clinical And Regulatory Obstacles Will Challenge Gastroenterology Prospects Despite Optimism

Fair Value: SEK 50 62.2% undervalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
CINPHA logo

Linaprazan Glurate Will Revolutionize Global Gastrointestinal Care

Fair Value: SEK 75 74.8% undervalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet with low risk.

3 Risks
1 Reward

Cinclus Pharma Holding AB (publ) Key Details

SEK 48.4m

Revenue

SEK 0

Cost of Revenue

SEK 48.4m

Gross Profit

SEK 225.5m

Other Expenses

-SEK 177.0m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Feb 18, 2026
-3.80
100.00%
-365.66%
0%
View Full Analysis

About CINPHA

Founded
2014
Employees
19
CEO
Christer Ahlberg
WebsiteView website
cincluspharma.com

Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company’s lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden.

Recent CINPHA News & Updates

Recent updates

No updates